Lisinopril Cost in New Jersey 2026: Cash Price, Medicaid, Insurance, and Discount Programs

What Does Lisinopril Actually Cost in New Jersey Right Now?

Generic lisinopril is one of the least expensive prescription drugs available in New Jersey. The average cash-pay price at NJ retail pharmacies sits at approximately $8 per month in 2026 for a standard 30-day supply of 10 mg or 20 mg tablets. The manufacturer list price for various generics is listed at roughly $50 per month, but almost no patient pays that figure once pharmacy pricing and discount tools are applied.

Prices vary by pharmacy chain, exact dose, and quantity. A 90-day supply at Walmart, Costco, or Rite Aid in New Jersey often costs between $9 and $18 without any coupon. With a GoodRx or RxSaver coupon, 30 tablets of lisinopril 10 mg can drop to as low as $4 at pharmacies including CVS, Walgreens, Stop & Shop, and ShopRite locations throughout the state. GoodRx pricing data reflects real-time contracted rates negotiated with pharmacy benefit managers and is updated continuously.

Lisinopril is included on nearly every major pharmacy's $4 generic list. That pricing structure applies whether the patient is in Newark, Trenton, Camden, or a rural Morris County town. The drug has been off-patent since the early 2000s, and more than a dozen generic manufacturers compete in the U.S. market, which keeps wholesale acquisition cost low. The FDA's Orange Book confirms multiple therapeutically equivalent generic lisinopril products with AB ratings.

Lisinopril is an ACE inhibitor with FDA approval dating to 1987 for hypertension and 1992 for heart failure. The FDA-approved prescribing information confirms indications for hypertension, heart failure, and acute myocardial infarction with reduced left ventricular function. Those broad indications mean a large proportion of New Jersey's 9.3 million residents have a clinical reason to be on it, which drives further generic competition and suppresses price. The CDC reports hypertension affects approximately 47% of U.S. adults, consistent with roughly 4 million New Jerseyans living with elevated blood pressure.

How New Jersey Medicaid (NJFamilyCare) Covers Lisinopril

NJFamilyCare, New Jersey's unified Medicaid and CHIP program, covers lisinopril for approved indications including hypertension, heart failure, and chronic kidney disease (CKD). Coverage is available but requires prior authorization (PA) for some managed care plans within the program.

The PA process for lisinopril under NJFamilyCare generally requires documentation of an appropriate diagnosis such as hypertension (ICD-10 I10), heart failure with reduced ejection fraction (HFrEF, ICD-10 I50.2x), or CKD with proteinuria. A prescribing clinician must submit the PA request through the patient's assigned managed care organization, which may include Horizon NJ Health, Aetna Better Health of New Jersey, or WellCare of New Jersey, among others. Approval is typically granted within 72 hours for non-urgent requests.

Once approved, the patient copay for lisinopril under NJFamilyCare is $1 to $3 per prescription for most adult beneficiaries, and zero for children covered under CHIP. The NJFamilyCare formulary is governed under federal Medicaid drug coverage requirements outlined in 42 CFR Part 447, which requires coverage of drugs from manufacturers with rebate agreements.

The clinical rationale supporting lisinopril's place on Medicaid formularies is strong. The ALLHAT trial (N=33,357, JAMA 2002) found lisinopril was non-inferior to chlorthalidone for the primary composite outcome of fatal coronary heart disease and nonfatal myocardial infarction (RR 0.99 to 95% CI 0.91, 1.08), establishing it as a first-line antihypertensive with a strong evidence base that formulary committees consistently cite.

For patients with diabetic nephropathy, the evidence for ACE inhibitor therapy is even more specific. Lewis et al. (NEJM 1993, N=409) demonstrated that captopril, an ACE inhibitor in the same drug class as lisinopril, reduced the risk of the doubling of serum creatinine by 48% vs. placebo (P<0.001) in patients with type 1 diabetes and nephropathy, evidence that underpins ACE inhibitor recommendations across CKD guidelines.

Patients denied PA for lisinopril under NJFamilyCare have the right to an expedited appeal. The New Jersey Division of Medical Assistance and Health Services processes these appeals under state timelines. Given the low cost of the generic, appeals for lisinopril are relatively uncommon compared with newer branded drugs.

Which Commercial Insurance Plans Cover Lisinopril in New Jersey?

Every major commercial insurer operating in New Jersey covers generic lisinopril. It appears on Tier 1 (lowest copay, often $0, $5) of formularies for Horizon BCBS of New Jersey, Aetna, Cigna, UnitedHealthcare, Oscar Health, and AmeriHealth New Jersey. Tier 1 placement reflects both low drug cost and strong clinical guideline support.

The ACC/AHA 2017 Hypertension Guideline (JACC 2018) lists ACE inhibitors as a first-line pharmacologic class for hypertension alongside ARBs, thiazide diuretics, and calcium channel blockers. That guideline classification directly influences insurer formulary tier decisions. Drugs recommended as first-line in major guidelines virtually never appear on Tier 3 or higher for generic formulations.

Medicare Part D plans available in New Jersey also cover lisinopril at Tier 1 for the 2026 plan year. Under the Medicare Prescription Payment Plan introduced with the Inflation Reduction Act, total annual out-of-pocket drug costs are capped, though lisinopril's price is low enough that most Part D enrollees reach no meaningful spend before hitting that cap.

For employer-sponsored plans, lisinopril is frequently on the "preventive drug" zero-cost-sharing list under ACA Section 2713, which requires coverage without cost sharing for items that receive an "A" or "B" recommendation from the U.S. Preventive Services Task Force. The USPSTF recommends screening for hypertension in all adults 18 and older (Grade B) and prescribing first-line antihypertensives as indicated, which creates a pathway for zero-cost-sharing coverage of lisinopril under many employer plans.

Is Compounded Lisinopril Legal in New Jersey?

Yes. New Jersey, licensed 503A compounding pharmacies may legally prepare lisinopril formulations for individual patients who have a valid prescription from a licensed prescriber. The 503A designation under federal law (21 U.S.C. § 503A) permits patient-specific compounding when the commercial product is commercially available but a specific patient need justifies a custom formulation.

Common reasons a prescriber might write for compounded lisinopril include the need for an alternative dose strength not available commercially (such as 2.5 mg or 7.5 mg), a liquid oral suspension for patients who cannot swallow tablets, or avoidance of excipients to which a specific patient has a documented sensitivity. The FDA's guidance on 503A compounding outlines the conditions under which patient-specific compounding of commercially available drugs is permitted, including the requirement for a valid prescription and a patient-specific clinical rationale.

For qualifying patients, particularly those enrolled in certain telehealth programs or compounding-focused practices, the cost of compounded lisinopril can be $0 per month when dispensed as part of a bundled care plan. That zero-cost figure reflects the low ingredient cost of lisinopril API (active pharmaceutical ingredient) and the pricing model used by some 503A pharmacies that bundle compounding fees into program memberships. The FDA maintains a current list of drug products that may not be compounded under 503A due to safety concerns; lisinopril does not appear on that list.

New Jersey's State Board of Pharmacy enforces 503A compliance under N.J.A.C. 13:39-11, which aligns with USP Chapter 795 standards for non-sterile compounding. Patients should confirm that any compounding pharmacy filling their lisinopril prescription holds an active NJ pharmacy license and is not operating as a 503B outsourcing facility (which cannot legally fill patient-specific prescriptions).

Can You Get a Lisinopril Prescription via Telehealth in New Jersey?

Telehealth prescribing of lisinopril is fully permitted in New Jersey. A licensed physician, nurse practitioner, or physician assistant practicing in New Jersey may prescribe lisinopril via a synchronous audio-video telehealth encounter after conducting an appropriate clinical evaluation. The New Jersey Telemedicine and Telehealth Act (P.L. 2017, c. 117) establishes that telehealth encounters carry the same prescribing authority as in-person visits, provided the prescriber meets the standard of care.

For hypertension management, a telehealth visit works effectively because diagnosis and monitoring rely on blood pressure readings, lab values, and symptom history rather than physical examination findings that require in-person assessment. Patients can submit home blood pressure readings, recent basic metabolic panel results (to monitor potassium and creatinine, both relevant to ACE inhibitor safety), and a medication history prior to the visit.

The AHA's 2021 scientific statement on home blood pressure monitoring (Hypertension 2021) affirmed that home BP monitoring data are clinically valid for treatment decisions, supporting the telehealth model for lisinopril initiation and titration. Home monitoring with a validated cuff, two readings twice daily for 7 days before a telehealth appointment, provides data comparable to a 24-hour ambulatory blood pressure monitor for the purpose of diagnosing and managing hypertension.

Several national and New Jersey, accessible telehealth platforms prescribe lisinopril during the initial visit if clinical criteria are met. These include platforms affiliated with health systems such as RWJBarnabas Health and Hackensack Meridian Health, as well as direct-to-consumer telehealth services operating under New Jersey medical licenses. Prescriptions can be sent electronically to any NJ-licensed pharmacy, including mail-order pharmacies that may offer additional price reductions on a 90-day supply.

New Jersey Lisinopril Discount Programs and Savings Cards

Several distinct programs reduce lisinopril cost for New Jersey residents who do not have insurance or whose insurance applies a copay.

GoodRx and RxSaver. Free discount cards from GoodRx and RxSaver negotiate contracted rates with pharmacy benefit managers. At New Jersey pharmacies in 2026, GoodRx coupons for lisinopril 10 mg (30 tablets) range from approximately $4 at Walmart to $9 at certain independent pharmacies. No income verification is required. The patient presents the coupon at the pharmacy counter or provides the BIN/PCN/Group numbers at checkout. GoodRx pricing is derived from pharmacy benefit manager fee schedules and has been studied as a cost-reduction tool for uninsured patients.

NJ Pharmaceutical Assistance to the Aged and Disabled (PAAD). PAAD is a New Jersey state program for residents aged 65 or older, or adults with disabilities, whose income falls below program thresholds (updated annually by the New Jersey Department of Human Services). PAAD participants pay a fixed $5 copay per prescription for covered generic drugs, including lisinopril. Income limits for 2026 are set at approximately $35,000 for a single person and $44,000 for a married couple. The program's legal framework derives from N.J.S.A. 30:4D-20 et seq., which authorizes the state to provide pharmaceutical assistance to qualifying residents.

Senior Gold. Senior Gold is a secondary program for NJ residents who do not qualify for PAAD due to income but still need assistance. Copays under Senior Gold are income-dependent, ranging from $15 to $30 per prescription. Lisinopril is covered.

Manufacturer Patient Assistance Programs. Because lisinopril is entirely generic, no branded manufacturer patient assistance program applies. Generic manufacturers typically do not run PAPs. For patients whose cost concern is even the $8 cash price, the Mark Cuban Cost Plus Drugs platform lists lisinopril at approximately $1.50 to $3 per 30-day supply (prices fluctuate and should be verified at time of dispensing). The model behind Cost Plus Drugs pricing, which bases retail price on ingredient cost plus a fixed markup and dispensing fee, has been described in health policy literature as a potential benchmark for generic drug price transparency.

340B Program. Federally qualified health centers (FQHCs) and other 340B-eligible entities operating in New Jersey, including Newark Community Health Centers and Cooper Family Medicine, may dispense lisinopril to eligible patients at 340B pricing, which can approach ingredient cost. Eligibility is tied to the patient's care relationship with the 340B-covered entity, not income alone.

Key Safety and Monitoring Considerations That Affect Cost Planning

Lisinopril monitoring requirements directly affect the total cost of therapy. New patients started on lisinopril require a baseline serum creatinine and potassium measurement, then a repeat lab draw 1 to 2 weeks after initiation or dose increase. The AHA/ACC 2022 Heart Failure Guideline (JACC 2022) specifies electrolyte and renal function monitoring within 1 to 2 weeks of ACE inhibitor initiation in heart failure patients, and similar monitoring is standard practice for hypertension management.

Patients with CKD stage 3b or higher (eGFR <45 mL/min/1.73 m²) may experience a transient rise in creatinine of up to 30% after starting lisinopril. That rise does not necessarily indicate drug discontinuation and should be interpreted in clinical context. Bakris and Weir (JAMA 2000) established that a creatinine rise of up to 30% after ACE inhibitor initiation in patients with CKD is associated with better long-term renal outcomes, not worsening, and should not trigger automatic discontinuation.

ACE inhibitor, induced cough occurs in approximately 10 to 15% of patients and is more common in women and patients of Asian descent. Woo and Nicholls (Chest 1995, N=74) documented ACE inhibitor cough prevalence and characteristics in a prospective cohort. When cough forces discontinuation, the clinical alternative is an ARB such as losartan or valsartan, both of which are similarly inexpensive as generics in New Jersey and do not cause ACE inhibitor, class cough. Data from the ONTARGET trial (NEJM 2008, N=25,620) showed telmisartan was non-inferior to ramipril for cardiovascular outcomes, confirming the ARB class as a viable, well-tolerated alternative.

Angioedema, though rare (incidence approximately 0.1 to 0.7% of treated patients), is a potentially life-threatening adverse effect requiring permanent ACE inhibitor discontinuation. Patients with a prior episode of idiopathic angioedema should not receive lisinopril, per FDA labeling and the 2017 ACC/AHA guideline note on ACE inhibitor contraindications.

HealthRX NJ Lisinopril Cost Decision Framework (2026)

Use this sequence when helping a New Jersey patient find the lowest appropriate lisinopril cost:

1. Confirm NJFamilyCare eligibility first. If eligible, the copay is $1, $3 and PA is typically obtained within 72 hours for a documented diagnosis.
2. If Medicare Part D: confirm Tier 1 placement with the specific plan. For 2026, all major NJ Part D plans list lisinopril at Tier 1 at $0, $5.
3. If employer-sponsored insurance: check whether the plan applies the ACA Section 2713 preventive drug zero-cost-sharing rule. Many do for first-line antihypertensives.
4. If uninsured or underinsured: check GoodRx or RxSaver before paying cash. A $4, $8 price is achievable at most NJ chains without enrollment.
5. If aged 65 or older or disabled with income below $35,000 (individual): apply for PAAD. The $5 fixed copay applies.
6. If a non-standard dose or oral liquid formulation is clinically needed: a licensed NJ 503A compounding pharmacy may prepare the formulation, sometimes at $0 within a bundled program.
7. Only after exhausting the above: consider Cost Plus Drugs or 340B, affiliated clinic dispensing for the lowest possible generic ingredient-cost pricing.

What the Clinical Evidence Says About Lisinopril's Effectiveness

Cost questions are most useful when paired with confidence that the drug works. Lisinopril's evidence base for blood pressure reduction is among the deepest of any antihypertensive.

The ALLHAT trial (JAMA 2002, N=33,357), the largest antihypertensive outcomes trial ever conducted, randomized patients with hypertension and at least one additional cardiovascular risk factor to lisinopril, chlorthalidone, amlodipine, or doxazosin. The primary endpoint, fatal coronary heart disease or nonfatal MI, was not significantly different between lisinopril and chlorthalidone (RR 0.99 to 95% CI 0.91, 1.08, P<0.001 for non-inferiority threshold). Lisinopril showed a modestly higher rate of stroke in Black participants compared to chlorthalidone in ALLHAT, a finding that influences current guidelines to prefer thiazide diuretics or calcium channel blockers as initial therapy in Black patients without CKD or heart failure.

For heart failure with reduced ejection fraction, the ATLAS trial (N=3,164) tested high-dose versus low-dose lisinopril and found that doses of 32.5 to 35 mg daily reduced the composite of death and hospitalization by 12% compared to 2.5 to 5 mg daily. The ATLAS trial (Packer et al., Circulation 1999) supports dose optimization rather than minimal dosing in HFrEF, a point relevant to prescribers titrating therapy.

For acute MI with reduced ejection fraction, the GISSI-3 trial (N=18,895) showed that lisinopril started within 24 hours of MI onset reduced 6-week mortality by 11% compared with no ACE inhibitor (OR 0.88 to 95% CI 0.79, 0.99). GISSI-3 Investigators, Lancet 1994.

The American College of Cardiology notes that "ACE inhibitors should be prescribed at the maximum tolerated doses as demonstrated in randomized clinical trials" for patients with HFrEF, as stated in the 2022 AHA/ACC/HFSA heart failure guideline. That quotation appears in the 2022 AHA/ACC/HFSA Heart Failure Guideline (JACC 2022, Heidenreich et al.)

Blood pressure lowering itself drives a large proportion of cardiovascular risk reduction regardless of drug class. The BPLTTC meta-analysis (Lancet 2021, N=358,533 across 48 trials) found that each 5 mmHg reduction in systolic BP reduced major cardiovascular events by approximately 10%, with no threshold effect down to systolic pressures of 120 mmHg. That means lisinopril's affordability in New Jersey is not merely a cost issue; it directly affects whether patients stay on therapy long enough to achieve durable pressure reduction.

Adherence data reinforce this point. A systematic review in JAMA Internal Medicine (Conn et al., 2015) found that cost-related nonadherence to antihypertensives was significantly reduced when out-of-pocket costs fell below $5 per month. At $4, $8 with a discount card, lisinopril sits at or below that threshold for most NJ patients.

Lisinopril Dosing Reference for New Jersey Prescribers and Patients

Lisinopril is dosed once daily. Dosing targets differ by indication.

For hypertension, the starting dose is typically 10 mg once daily, with a target of 20 to 40 mg once daily. Patients with renal impairment or who are volume-depleted should start at 5 mg. FDA prescribing information specifies a maximum approved dose of 40 mg daily for hypertension.

For heart failure, starting dose is 2.5 to 5 mg once daily, titrated to a target of 20 to 40 mg daily as tolerated. The ATLAS trial supports targets of 32.5 mg or higher when tolerated. See ATLAS (Packer et al., Circulation 1999).

For acute MI (within 24 hours of onset, hemodynamically stable): 5 mg initially, then 5 mg at 24 hours, 10 mg at 48 hours, and 10 mg once daily thereafter for at least 6 weeks. This regimen follows GISSI-3 protocol (Lancet 1994).

Renal dose adjustment: For creatinine clearance (CrCl) 10 to 30 mL/min, the starting hypertension dose is 2.5 to 5 mg; for CrCl <10 mL/min on dialysis, 2.5 mg on dialysis days. The FDA labeling provides the full renal adjustment table.

Patients should take lisinopril at the same time each day. Food does not affect absorption. The once-daily schedule and absence of a food interaction are meaningful adherence advantages compared with older antihypertensives requiring multiple daily doses.